



# SPECIALTY MEDICATIONS

available through **Accredo Health Group, Inc., an Express Scripts specialty pharmacy**

Call toll-free (800) 803-2523, 8:00 am to 8:00 pm, eastern time, Monday through Friday, to confirm that your medication is covered.

**Effective as of January 1, 2018**

- ◆ *Abraxane*<sup>®</sup> (paclitaxel protein-bound particles) [PA]
- Actemra*<sup>™</sup> (tocilizumab) [PA] [QD] [ST]
- Actemra*<sup>™</sup> SQ (tocilizumab) [PA] [QD] [PICA] [ST]
- ◆ *Actimmune*<sup>®</sup> (interferon gamma-1b) [PA][PICA]
- ◆ *Adcetris*<sup>®</sup> (brentuximab vedotin) [PA]
- Adcirca*<sup>®</sup> (tadalafil) [PA] [ST] [QD]
- Adempas*<sup>®</sup> (riociguat) [PA]
- Advate*<sup>®</sup> (antihemophilic factor [recombinant]) [CPA]
- Adynovate*<sup>™</sup> (antihemophilic Factor VIII [recombinant]) [CPA]
- ◆ *Afinitor*<sup>®</sup> (everolimus) [PA] [QD] [PICA]
- Afstyla*<sup>®</sup> (antihemophilic Factor [recombinant]) [CPA]
- ◆ *Alcensa*<sup>®</sup> (alectinib) [PA] [PICA] [QD] [SF]
- Aldurazyme*<sup>®</sup> (laronidase) [CPA]
- Alphanate*<sup>®</sup> (antihemophilic factor [human]) [CPA]
- AlphaNine*<sup>®</sup> SD (coagulation factor IX [human]) [CPA]
- Alprolix*<sup>™</sup> (coagulation factor IX [recombinant]) [CPA]
- ◆ *Alunbrig*<sup>™</sup> (brigatinib) [PA] [PICA]
- Ampyra*<sup>™</sup> (dalfampridine) [PA] [QD]
- Apokyn*<sup>®</sup> (apomorphine hydrochloride) [QD]
- Aralast*<sup>®</sup> NP (alpha[1]-proteinase inhibitor [human]) [PA]
- ◆ *Aranesp*<sup>®</sup> (darbepoetin alfa) [PA] [PICA]
- Arcalyst*<sup>®</sup> (rilonacept) [PA] [QD] [PICA]
- \**Arixtra*<sup>®</sup> (fondaparinux sodium) [PICA]
- ◆ *Arranon*<sup>®</sup> (nelarabine) [PA]
- ◆ *Arzerra*<sup>®</sup> (ofatumumab) [PA]
- Aubagio*<sup>®</sup> (teriflunomide) [PA] [ST]
- ◆ *Avastin*<sup>®</sup> (bevacizumab) [PA] [QD]
- Avonex*<sup>®</sup> (interferon beta-1a) [PA] [PICA]
- Azacitidine (GENERIC) [PA] [QD]
- Bebulin*<sup>®</sup> VH (factor IX complex) [CPA]
- ◆ *Bendeka*<sup>™</sup> (bendamustine) [PA]
- BeneFIX*<sup>®</sup> (coagulation factor IX [recombinant]) [CPA]
- Benlysta*<sup>®</sup> (belimumab) [PA]
- Berinert*<sup>®</sup> (c1 esterase inhibitor [human]) [PA] [QD]
- Betaseron<sup>®</sup> (interferon beta-1b) [PA] [PICA]
- Bethkis*<sup>®</sup> (tobramycin)
- Bexarotene* (GENERIC)
- Bivigam*<sup>™</sup> (immune globulin intravenous [human]) [PA]
- ◆ *Bosulif*<sup>®</sup> (bosutinib) [PA] [SF] [QD]
- Botox*<sup>®</sup> (botulinum toxin type A) [PA] [PICA]
- ◆ Capecitabine (GENERIC) [PICA]
- Carbaglu*<sup>™</sup> (carglumic acid)
- Carimune*<sup>®</sup> NF (immune globulin intravenous [human]) [PA]
- Cayston*<sup>®</sup> (aztreonam) [PA] [QD]
- Cerdelga*<sup>®</sup> (eliglustat tartrate)
- Cerezyme*<sup>®</sup> (imiglucerase) [CPA] [ST]
- Cimzia*<sup>®</sup> (certolizumab pegol) [ST] [PA] [QD] [PICA]
- Cinryze*<sup>®</sup> (c1 esterase inhibitor) [PA] [QD]
- ◆ *Cabometyx*<sup>™</sup> (cobozantinib) [PA][QD] [SF]
- Copaxone*<sup>®</sup> (glatiramer acetate) [PA] [PICA]
- Copegus*<sup>®</sup> (ribavirin) [PA] [SF]
- Corifact*<sup>®</sup> (factor XIII [human]) [CPA]
- Cosentyx*<sup>®</sup> (secukinumab) [PA] [PICA]
- ◆ *Cotellic*<sup>®</sup> (cobimetinib) [PA] [PICA] [QD]
- Cuvitru*<sup>™</sup> (immune globulin 20% [human])
- ◆ *Cyramza*<sup>®</sup> (ramucirumab) [PICA]

◆ If the indication is CANCER, and the drug is subject to management by EviCore Comprehensive Oncology Management Program, please contact (888) 910-1199 for additional assistance. Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization.

\*This specialty drug may be filled two (2) times at a retail pharmacy on an emergency basis. Subsequent fills must be made through Accredo's mail order delivery.

[PICA] = Specialty drug is available through the NYC Municipal Program called PICA. NYC Municipal employees can contact Accredo Customer Service at (800) 467-2006 and inquire about drug coverage.

The symbol [PA] next to a drug name indicates that this medication is subject to the Prior Authorization Program.

The symbol [ST] next to a drug name indicates that this medication is subject to the Step Therapy Program.

The symbol [QD] next to a drug name indicates that this medication is subject to the Quantity Duration Program.

The symbol [CPA] next to a drug name indicates that this medication is subject to the Client Prior Authorization Program.

The symbol [SF] next to a drug name indicates that this medication is subject to the Split-Fill Program.

All rights in the product names of all third-party products listed, whether or not appearing with the trademark symbol, belong exclusively to their respective owners. Subject to change.

*CytoGam*<sup>®</sup> (cytomegalovirus immune globulin intravenous [human]) [CPA]  
*Cytovene*<sup>®</sup> IV (ganciclovir sodium)  
*Daklinza*<sup>™</sup> (daclatasvir) [PA] [QD] [SF]  
 ◆ *Darzalex*<sup>®</sup> (daratumumab) [PA]  
 ◆ Decitabine (GENERIC)  
*Duopa*<sup>®</sup> (levodopa/carbidopa)  
*Dupixent*<sup>®</sup> (dupilumab) [PA] [QD]  
*Dysport*<sup>®</sup> (abobotulinumtoxinA) [PA]  
*Egrifta*<sup>®</sup> (tesamorelin) [PICA]  
*Elaprase*<sup>®</sup> (idursulfase) [CPA]  
*Elelyso*<sup>™</sup> (taliglucerase alfa)  
 ◆ *Eligard*<sup>®</sup> (leuprolide acetate) [PA][PICA]  
*Eloctate*<sup>™</sup> (antihemophilic factor [recombinant]) [CPA]  
 ◆ *Empliciti*<sup>™</sup> (elotuzumab) [PA]  
*Enbrel*<sup>®</sup> (etanercept) [PA] [QD] [PICA][ST]  
 \*Enoxaparin sodium (GENERIC) [PICA]  
*Entyvio*<sup>®</sup> (vedolizumab) [PA]  
*Epclusa*<sup>®</sup> (sofosbuvir/velpatasvir) [PA][QD][SF]  
 ◆ *Epogen*<sup>®</sup> (epoetin alfa) [PA] [PICA]  
 Epoprostenol sodium (GENERIC) [ST]  
 ◆ *Erbitux*<sup>®</sup> (cetuximab) [PA] [QD]  
 ◆ *Erivedge*<sup>™</sup> (vismodegib) [PA] [QD] [SF]  
*Esbriet*<sup>®</sup> (pirfenidone) [PA]  
*Euflexxa*<sup>®</sup> (sodium hyaluronate) [PA] [QD]  
*Exjade*<sup>®</sup> (deferasirox) [SF]  
*Extavia*<sup>®</sup> (interferon beta-1b) [ST] [PA] [PICA]  
*Eylea*<sup>™</sup> (aflibercept) [PA]  
*Fabrazyme*<sup>®</sup> (agalsidase beta) [CPA]  
 ◆ *Farydak* (panobinostat) [PA] [PICA] [QD]  
*Feiba*<sup>®</sup> VH (anti-inhibitor coagulant complex) [CPA]  
*Firazyr*<sup>®</sup> (icatibant) [PA] [QD] [PICA]  
 ◆ *Firmagon*<sup>®</sup> (degarelix) [PA] [PICA]  
*Flebogamma*<sup>®</sup> (immune globulin [human]) [PA]  
*Flolan*<sup>®</sup> (epoprostenol sodium) [PA]  
 ◆ *Folotyng*<sup>™</sup> (pralatrexate) [PA]  
 \*Fondaparinux sodium (GENERIC) [PICA]  
*Forteo*<sup>®</sup> (teriparatide [rDNA origin]) [PA] [PICA]  
 \**Fragmin*<sup>®</sup> (dalteparin sodium) [PICA]

*GamaSTAN*<sup>®</sup> S/D (immune globulin [human])  
*Gammagard*<sup>®</sup> Liquid (immune globulin [human]) [PA]  
*Gammagard*<sup>®</sup> S/D (immune globulin [human]) [PA]  
*Gammaked*<sup>™</sup> (immune globulin, gamma caprylate [IGG]) [PA]  
*Gammaplex*<sup>®</sup> (immune globulin [human]) [PA]  
*Gamunex*<sup>®</sup> (immune globulin [human]) [PA]  
 Ganciclovir (GENERIC)  
*Gattex*<sup>®</sup> (teduglutide)  
 ◆ *Gazyva*<sup>™</sup> (obinutuzumab) [PA]  
*Gel-One*<sup>®</sup> (hyaluronate sodium) [PA]  
*Gelsyn-3*<sup>™</sup> (hyaluronate sodium) [PA]  
*Genotropin*<sup>®</sup> (somatropin [rDNA origin]) [PA] [PICA]  
*Gilenya*<sup>™</sup> (afatinib) [PA] [ST]  
 ◆ *Gilotrif*<sup>™</sup> (afatinib) [PA] [PICA] [QD]  
*Glassia*<sup>™</sup> (alpha [1]-proteinase inhibitor [human]) [PA] [ST]  
 Glatiramer (GENERIC) [PA] [PICA]  
*Glatopa*<sup>®</sup> (glatiramer acetate) [PA] [PICA]  
 ◆ *Granix*<sup>™</sup> (tbo-filgrastim) [PA] [PICA]  
*Haegarda*<sup>®</sup> (c1 esterase inhibitor) [PA] [PICA]  
 ◆ *Halaven*<sup>™</sup> (eribulin mesylate) [PA]  
*Harvoni*<sup>™</sup> (ledipasvir/sofosbuvir) [PA] [QD] [SF]  
*Helixate*<sup>®</sup> FS (antihemophilic factor [recombinant]) [CPA]  
*Hemofil*<sup>®</sup> M (antihemophilic factor [human]) [CPA]  
 ◆ *Herceptin*<sup>®</sup> (trastuzumab) [PA]  
*Hetlioz*<sup>™</sup> (tasimelteon) [PA]  
*Hizentra*<sup>™</sup> (immune globulin subcutaneous [human]) [PA]  
*H.P. Acthar*<sup>®</sup> Gel (corticotropin) [PA] [QD]  
*Humate-P*<sup>®</sup> (antihemophilic factor/von Willebrand factor complex [human]) [CPA]  
*Humatrope*<sup>®</sup> (somatropin [rDNA origin]) [PA] [PICA]  
*Humira*<sup>®</sup> (adalimumab) [PA] [QD] [PICA]  
*Hyalgan*<sup>®</sup> (sodium hyaluronate) [PA] [QD]  
 ◆ *Hycamtin*<sup>®</sup> capsules (topotecan) [PA]  
*Hymovis*<sup>®</sup> (hyaluronate sodium) [PA]  
*HyperRho*<sup>®</sup> S/D (Rho[D] immune globulin [human])

◆ If the indication is CANCER, and the drug is subject to management by EviCore Comprehensive Oncology Management Program, please contact (888) 910-1199 for additional assistance. Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization.

\*This specialty drug may be filled two (2) times at a retail pharmacy on an emergency basis. Subsequent fills must be made through Accredo's mail order delivery.

[PICA] = Specialty drug is available through the NYC Municipal Program called PICA. NYC Municipal employees can contact Accredo Customer Service at (800) 467-2006 and inquire about drug coverage.

The symbol [PA] next to a drug name indicates that this medication is subject to the Prior Authorization Program.

The symbol [ST] next to a drug name indicates that this medication is subject to the Step Therapy Program.

The symbol [QD] next to a drug name indicates that this medication is subject to the Quantity Duration Program.

The symbol [CPA] next to a drug name indicates that this medication is subject to the Client Prior Authorization Program.

The symbol [SF] next to a drug name indicates that this medication is subject to the Split-Fill Program.

All rights in the product names of all third-party products listed, whether or not appearing with the trademark symbol, belong exclusively to their respective owners. Subject to change.

*Hyqvia*<sup>™</sup> (immune globulin infusion 10% [human] with recombinant) [PA]  
 ◆ *Ibrance*<sup>®</sup> (palbociclib) [PA] [PICA] [QD]  
*Idelvion*<sup>®</sup> (coagulation factor IX [recombinant]) [CPA]  
 ◆ *Idhifa*<sup>®</sup> (enasidenib) [PICA]  
*Ilaris*<sup>®</sup> (canakinumab) [PA] [QD]  
*Iluvien*<sup>®</sup> (Fluocinolone)  
 ◆ Imatinib (GENERIC) [PA] [PICA] [QD]  
 ◆ *Imfinzi*<sup>™</sup> (durvalumab) [PA]  
*Increlex*<sup>®</sup> (mecasermin [rDNA origin]) [PA] [PICA]  
*Inflextra*<sup>™</sup> (infliximab-dyyb) [PA] [ST]  
 ◆ *Inlyta*<sup>®</sup> (axitinib) [PA] [QD] [PICA] [SF]  
 ◆ *Intron*<sup>®</sup> A (interferon alfa-2b) [PA] [PICA]  
 \**Privask*<sup>®</sup> (desirudin)  
 ◆ *Iressa*<sup>®</sup> [PA] [PICA] [QD] [SF]  
 ◆ *Istodax*<sup>®</sup> (romidepsin) [PA] [QD]  
 ◆ *Ixempra*<sup>®</sup> (ixabepilone) [PA]  
*Ixinity*<sup>®</sup> (coagulation factor IX [recombinant]) [CPA]  
*Jadenu*<sup>™</sup> (deferasirox) [SF]  
 ◆ *Jakafi*<sup>™</sup> (ruxolitinib) [PA] [SF] [QD]  
 ◆ *Jevtana*<sup>®</sup> (cabazitaxel) [PA] [QD]  
*Juxtapid*<sup>®</sup> (lomitapide)  
 ◆ *Kadcyla*<sup>™</sup> (ado-trastuzumab emtansine) [PA]  
*Kalbitor*<sup>®</sup> (ecallantide) [PA] [QD]  
*Kalydeco*<sup>™</sup> (ivacaftor) [PA] [SF]  
*Kanuma*<sup>™</sup> (sebelipase alfa)  
*Kevzara*<sup>®</sup> (sarilumab) [QD] [PA] [PICA]  
 ◆ *Kisqali*<sup>®</sup> (ribociclib) [PA] [QD] [PICA]  
*Kitabis Pak*<sup>®</sup> (Tobramycin)  
*Koate*<sup>®</sup>-DVI (antihemophilic factor [human]) [CPA]  
*Kogenate*<sup>®</sup> FS (antihemophilic factor [recombinant]) [CPA]  
*Kovaltry*<sup>®</sup> (antihemophilic factor VIII) [CPA]  
*Krystexxa*<sup>™</sup> (pegloticase) [PA]  
*Kuvan*<sup>®</sup> (sapropterin dihydrochloride) [PA]  
*Kynamro*<sup>™</sup> (mipomersen sodium)  
 ◆ *Lartruvo*<sup>™</sup> (olaratumab) [PA]  
*Lemtrada*<sup>™</sup> (alemtuzumab) [PA]  
 ◆ *Lenvima*<sup>™</sup> (lenvatinib) [PA] [PICA] [SF]

*Letairis*<sup>®</sup> (ambrisentan) [PA] [QD]  
 ◆ *Leukine*<sup>®</sup> (sargramostim) [PA] [PICA]  
 Leuprolide acetate (GENERIC) [PICA]  
*Liletta*<sup>™</sup> (levonorgestrel-releasing intrauterine device)  
 ◆ *Lonsurf*<sup>®</sup> (tipiracil/trifluridine) [PA] [PICA]  
 \**Lovenox*<sup>®</sup> (enoxaparin sodium) [PICA]  
*Lucentis*<sup>®</sup> (ranibizumab) [PA]  
*Lumizyme*<sup>™</sup> (alglucosidase alfa) [CPA]  
*Lupaneta*<sup>™</sup> (leuprolide acetate) [PICA]  
*Lupron Depot*<sup>®</sup> (leuprolide acetate) [PA] [PICA]  
*Lupron Depot-PED*<sup>®</sup> (leuprolide acetate) [PA] [PICA]  
 ◆ *Lynparza*<sup>™</sup> (olaparib) [PA] [SF] [PICA]  
*Macugen*<sup>®</sup> (pegaptanib sodium injection) [PA]  
*Makena*<sup>™</sup> (hydroxyprogesterone caproate) [PA]  
*Mavyret*<sup>™</sup> (glecaprevir/pibrentasvir) [QD] [SF] [PA]  
 ◆ *Mekinist*<sup>™</sup> (trametinib) [PA] [PICA] [QD]  
*MICRhoGAM*<sup>®</sup> (Rho[D] immune globulin [human])  
 Mitoxantrone HCl (GENERIC)  
*Moderiba*<sup>™</sup> (ribavirin) [PA]  
*Monoclate-P*<sup>®</sup> (antihemophilic factor [human]) [CPA]  
*Mononine*<sup>®</sup> (coagulation factor IX [human]) [CPA]  
 ◆ *Mozobil*<sup>®</sup> (plerixafor) [QD] [PA] [PICA]  
*Myalept*<sup>™</sup> (metreleptin) [PA] [PICA]  
*Myobloc*<sup>®</sup> (botulinum toxin type B) [PA] [PICA]  
*Naglazyme*<sup>®</sup> (galsulfase) [CPA]  
*Natpara*<sup>®</sup> (parathyroid hormone) [PA] [PICA]  
 ◆ *Nerlynx*<sup>™</sup> (neratinib) [PICA]  
 ◆ *Neulasta*<sup>®</sup> (pegfilgrastim) [PA] [PICA]  
*Neumega*<sup>®</sup> (oprelvekin) [PICA]  
 ◆ *Neupogen*<sup>®</sup> (filgrastim) [PA] [PICA]  
 ◆ *Nexavar*<sup>®</sup> (sorafenib) [PA] [QD] [PICA] [SF]  
 ◆ *Ninlaro*<sup>®</sup> (ixazomib) [PA] [PICA] [QD]  
*Norditropin*<sup>®</sup> (somatropin [rDNA origin]) [PA] [PICA]  
*Norditropin/Nordiflex*<sup>®</sup> (somatropin [rDNA origin]) [PA] [PICA]  
*Northera*<sup>®</sup> (droxidopa) [PA]

◆ If the indication is CANCER, and the drug is subject to management by EviCore Comprehensive Oncology Management Program, please contact (888) 910-1199 for additional assistance. Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization.

\*This specialty drug may be filled two (2) times at a retail pharmacy on an emergency basis. Subsequent fills must be made through Accredo's mail order delivery.

[PICA] = Specialty drug is available through the NYC Municipal Program called PICA. NYC Municipal employees can contact Accredo Customer Service at (800) 467-2006 and inquire about drug coverage.

The symbol [PA] next to a drug name indicates that this medication is subject to the Prior Authorization Program.

The symbol [ST] next to a drug name indicates that this medication is subject to the Step Therapy Program.

The symbol [QD] next to a drug name indicates that this medication is subject to the Quantity Duration Program.

The symbol [CPA] next to a drug name indicates that this medication is subject to the Client Prior Authorization Program.

The symbol [SF] next to a drug name indicates that this medication is subject to the Split-Fill Program.

All rights in the product names of all third-party products listed, whether or not appearing with the trademark symbol, belong exclusively to their respective owners. Subject to change.

*NovoEight*<sup>®</sup> (antihemophilic factor VIII [recombinant]) [CPA]  
*NovoSeven*<sup>®</sup> *RT* (coagulation factor VIIa [recombinant]) [CPA]  
*Nplate*<sup>®</sup> (romiplostim) [PA]  
*Nucala*<sup>™</sup> (mepolizumab) [PA]  
*Nuplazid*<sup>™</sup>[SF]  
*Nutropin*<sup>®</sup> (somatropin [rDNA origin]) [PA] [PICA]  
*Nutropin AQ*<sup>®</sup> (somatropin [rDNA origin]) [PA] [PICA]  
*Nuwiq*<sup>®</sup> (antihemophilic Factor VIII [recombinant]) [CPA]  
*Ocaliva*<sup>™</sup> (obeticholic acid) [PA][QD]  
*Ocrevus*<sup>™</sup> (ocrelizumab) [PA] [ST]  
*Octagam*<sup>®</sup> (immune globulin intravenous [human]) [PA]  
 Octreotide acetate (GENERIC)  
 ♦ *Odomzo*<sup>®</sup> (*sonidegib*) [PA][PICA]  
*Ofev*<sup>®</sup> (Nintedanib) [PA]  
*Olysio*<sup>™</sup> (simeprevir) [PA] [SF]  
*Omnitrope*<sup>®</sup> (somatropin) [PA] [PICA]  
 ♦ *Opdivo*<sup>®</sup> (Nivolumab) [PA]  
*Opsumit*<sup>®</sup> (macitentan) [PA]  
*Orencia*<sup>®</sup> *IV* (abatacept intravenous) [PA] [PICA]  
*Orencia*<sup>®</sup> *SC* (abatacept subcutaneous) [ST] [PA] [QD] [PICA]  
*Orenitram*<sup>™</sup> (treprostinil) [PA]  
*Orkambi*<sup>®</sup> (lumacaftor/ivacaftor) [PA]  
*OrthoVisc*<sup>®</sup> (hyaluronate sodium) [PA]  
*Otezla*<sup>®</sup> (apremilast) [PA] [ST]  
*Ozurdex*<sup>™</sup> (dexamethasone)  
 ♦ *Pegasys*<sup>®</sup> (peginterferon alfa-2a) [PA] [PICA] [SF]  
 ♦ *Perjeta*<sup>™</sup> (pertuzumab) [PA]  
*Plegridy*<sup>™</sup> (peginterferon Beta-1A) [PA] [PICA]  
 ♦ *Pomalyst*<sup>®</sup> (pomalidomide) [PA] [PICA]  
 ♦ *Portrazza*<sup>®</sup> (necitumumab) [PICA]  
*Praluent*<sup>®</sup> (alirocumab) [PA]  
*Privigen*<sup>®</sup> (immune globulin intravenous [human]) [PA]  
 ♦ *Procrit*<sup>®</sup> (epoetin alfa) [PA] [PICA]  
*Procysbi*<sup>™</sup> (cysteamine bitartrate)  
*Profilnine*<sup>®</sup> *SD* (factor IX complex [human]) [CPA]  
 ♦ *Proleukin*<sup>®</sup> (aldesleukin) [PA]  
*Prolia*<sup>™</sup> (denosumab) [PA] [QD]  
*Promacta*<sup>®</sup> (eltrombopag) [PA] [QD]  
*ProThelial*<sup>™</sup> (sucralfate)  
*Pulmozyme*<sup>®</sup> (dornase alfa)  
*Ravicti*<sup>™</sup> (glycerol phenylbuterate)  
*Rebetol*<sup>®</sup> (ribavirin) [PA]  
*Rebif*<sup>®</sup> (interferon beta-1a) [PA] [PICA]  
*Recombinate*<sup>™</sup> (antihemophilic factor [recombinant]) [CPA]  
*Remicade*<sup>®</sup> (infliximab) [PA]  
*Remodulin*<sup>®</sup> (treprostinil sodium) [ST]  
*Repatha*<sup>™</sup> (evolocumab) [PA]  
*Retisert*<sup>®</sup> (fluocinolone acetonide) [QD]  
*Revatio*<sup>®</sup> *injection* (sildenafil citrate) [PA] [QD]  
*Revatio*<sup>®</sup> *tablets* (sildenafil citrate) [PA] [QD]  
 ♦ *Revlimid*<sup>®</sup> (lenalidomide) [PA] [QD] [PICA]  
*RhoGAM*<sup>®</sup> (RHo[D] immune globulin [human])  
*Rhophylac*<sup>®</sup> (RHo[D] immune globulin intravenous [human])  
*RiaSTAP*<sup>®</sup> (fibrinogen)  
*RibaPak*<sup>®</sup> (GENERIC) [PA]  
*Ribasphere*<sup>®</sup> (GENERIC) [PA] [SF]  
*Ribavirin* (GENERIC) [PA] [SF]  
 ♦ *Rituxan*<sup>®</sup> (rituximab) [PA]  
*Rixubis*<sup>™</sup> (coagulation factor IX [recombinant]) [CPA]  
*Ruconest*<sup>™</sup> (c1 Esterase Inhibitor [recombinant]) [PA]  
 ♦ *Rydapt*<sup>®</sup> (midostaurin) [PA]  
*Sabril*<sup>®</sup> (vigabatrin)  
*Saizen*<sup>®</sup> (somatropin [rDNA origin]) [PA] [PICA]  
*Samsca*<sup>®</sup> (tolvaptan) [QD]  
*Sandostatin*<sup>®</sup> (octreotide acetate) [PICA]  
*Sandostatin LAR*<sup>®</sup> (octreotide/IM) [PICA]  
*Serostim*<sup>®</sup> (somatropin [rDNA origin]) [PA] [PICA]  
*Signifor*<sup>®</sup> (pasireotide dispartate) [PA]  
*Signifor*<sup>®</sup> *LAR* (pasireotide pamoate) [PA] [PICA]  
*Sildenafil* (GENERIC) [ST] [QD]

♦ If the indication is CANCER, and the drug is subject to management by EviCore Comprehensive Oncology Management Program, please contact (888) 910-1199 for additional assistance. Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization.

\*This specialty drug may be filled two (2) times at a retail pharmacy on an emergency basis. Subsequent fills must be made through Accredo's mail order delivery.

[PICA] = Specialty drug is available through the NYC Municipal Program called PICA. NYC Municipal employees can contact Accredo Customer Service at (800) 467-2006 and inquire about drug coverage.

The symbol [PA] next to a drug name indicates that this medication is subject to the Prior Authorization Program.

The symbol [ST] next to a drug name indicates that this medication is subject to the Step Therapy Program.

The symbol [QD] next to a drug name indicates that this medication is subject to the Quantity Duration Program.

The symbol [CPA] next to a drug name indicates that this medication is subject to the Client Prior Authorization Program.

The symbol [SF] next to a drug name indicates that this medication is subject to the Split-Fill Program.

All rights in the product names of all third-party products listed, whether or not appearing with the trademark symbol, belong exclusively to their respective owners. Subject to change.

*Siliq* (brodalumab)<sup>™</sup> [QD] [PA] [PICA]  
*Simponi*<sup>™</sup> (golimumab) [ST] [PA] [QD] [PICA]  
*Simponi*<sup>™</sup> ARIA<sup>™</sup> (golimumab) [ST] [PA] [QD] [PICA]  
*Soliris*<sup>®</sup> (eculizumab)  
*Somatuline Depot*<sup>®</sup> (lanreotide) [PICA]  
*Somavert*<sup>®</sup> (pegvisomant)  
*Sovaldi*<sup>™</sup> (sofosbuvir) [PA] [QD] [SF]  
*Spinraza*<sup>™</sup> (nusinersen) [PA]  
♦ *Sprycel*<sup>®</sup> (dasatinib) [PA] [QD] [PICA] [SF]  
*Stelara*<sup>™</sup> (ustekinumab) [PA] [QD] [PICA]  
*Stimate*<sup>®</sup> (desmopressin acetate)  
♦ *Stivarga*<sup>®</sup> (regorafenib) [PA] [QD]  
*Supartz*<sup>®</sup> (sodium hyaluronate) [PA] [QD]  
*Supprelin*<sup>®</sup> LA (histrelin acetate)  
♦ *Sutent*<sup>®</sup> capsules (sunitinib malate) [PICA] [QD]  
*Sylatron*<sup>™</sup> (peginterferon alfa-2b)  
*Sylvant*<sup>™</sup> (siltuximab)  
*Synagis*<sup>®</sup> (palivizumab) [PA] [QD]  
*Synvisc*<sup>®</sup>/Synvisc-ONE<sup>®</sup> (hylan G-F 20) [PA] [QD]  
♦ *Tafinlar*<sup>®</sup> (dabrafenib) [PA] [PICA] [QD] [SF]  
♦ *Tagrisso*<sup>™</sup> (osimertinib) [PA] [PICA] [QD]  
*Taltz*<sup>®</sup> (ixekizumab) [PA] [QD] [PICA] [ST]  
♦ *Tarceva*<sup>®</sup> (erlotinib) [PA] [QD] [PICA] [SF]  
♦ *Tasigna*<sup>®</sup> (nilotinib) [PA] [QD] [PICA] [SF]  
♦ *Tecentriq*<sup>™</sup> (atezolizumab) [PA]  
*Tecfidera*<sup>™</sup> (dimethyl fumarate) [PA] [ST]  
*Technivie*<sup>™</sup> (ombitasvir/paritaprevir/ritonavir) [PA] [SF]  
♦ *Temodar*<sup>®</sup> (temozolomide) [PA] [PICA]  
Temozolomide (GENERIC) [PICA]  
Tetrabenazine (GENERIC)  
♦ *Thalomid*<sup>®</sup> (thalidomide) [PA] [PICA]  
*Tobi*<sup>®</sup> (tobramycin)  
*Tobi-Podhaler*<sup>®</sup> (tobramycin)  
Tobramycin (GENERIC)  
♦ *Torise*<sup>®</sup> (temsrolimus) [PA]  
*Tracleer*<sup>®</sup> (bosentan) [PA] [QD]  
♦ *Treanda*<sup>®</sup> (bendamustine) [PA]  
*Tremfya*<sup>™</sup> (guselkumab) [PA] [ST] [PICA]

*Tretten*<sup>®</sup> (coagulation factor XIII A-subunit [recombinant]) [CPA]  
♦ *Tykerb*<sup>®</sup> (lapatinib) [PA] [QD] [PICA]  
*Tymlos*<sup>™</sup> (abaloparatide) [PA] [PICA]  
*Tysabri*<sup>®</sup> (natalizumab) [PA] [QD]  
*Tyvaso*<sup>®</sup> (treprostinil) [PA]  
*Uptravi*<sup>®</sup> (selexipag)  
♦ *Valchlor*<sup>™</sup> (mechlorethamine) [PA]  
♦ *Vantas*<sup>®</sup> (histrelin) [PA]  
♦ *Vectibix*<sup>®</sup> (panitumumab) [PA]  
♦ *Velcade*<sup>®</sup> (bortezomib) [PA]  
*Veletri*<sup>®</sup> (epoprostenol sodium)  
*Veltassa*<sup>™</sup> (paitromer)  
*Ventavis*<sup>®</sup> (iloprost) [PA] [QD]  
♦ *Verzenio*<sup>™</sup> (abemaciclib) [PICA] [SF]  
♦ *Vidaza*<sup>®</sup> (azacitidine) [PA] [QD] [PICA]  
*Viekira Pak* (ombitasvir/paritaprevir/ritonavir co-packed with dasabuvir) [PA] [QD] [SF]  
Vigabatrin (GENERIC)  
*Vimizim*<sup>™</sup> (elosulfase alfa) [CPA]  
*Visudyne*<sup>®</sup> (verteporfin)  
*Vivitrol*<sup>®</sup> (naltrexone)  
*Vosevi*<sup>®</sup> (sofosbuvir/velpatasvir/voxilaprevir) [QD] [SF] [PA]  
♦ *Votrient*<sup>®</sup> (pazopanib) [PA] [QD] [PICA] [SF]  
*Vpriv*<sup>™</sup> (velaglucerase alfa) [CPA]  
*Wilate*<sup>®</sup> (von Willebrand factor/coagulation factor VIII complex [human]) [CPA]  
*WinRho SDF*<sup>®</sup> (Rho[D] immune globulin intravenous [human])  
♦ *Xalkori*<sup>®</sup> (crizotinib) [PA] [QD] [PICA] [SF]  
*Xeljanz*<sup>®</sup> (tofacitinib citrate) [PA]  
*Xeljanz XR*<sup>®</sup> (tofacitinib) [PA]  
*Xenazine*<sup>®</sup> (tetrabenazine) [PA] [QD] [SF]  
*Xeomin*<sup>®</sup> (incobotulinumtoxinA) [PA]  
♦ *Xgeva*<sup>™</sup> (denosumab) [QD]  
*Xolair*<sup>®</sup> (omalizumab) [PA] [QD]  
♦ *Xtandi*<sup>®</sup> (enzalutamide) [PA] [QD] [SF]  
*Xyntha*<sup>®</sup> (antihemophilic factor [recombinant]) [CPA]

♦ If the indication is CANCER, and the drug is subject to management by EviCore Comprehensive Oncology Management Program, please contact (888) 910-1199 for additional assistance. Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization.

\*This specialty drug may be filled two (2) times at a retail pharmacy on an emergency basis. Subsequent fills must be made through Accredo's mail order delivery.

[PICA] = Specialty drug is available through the NYC Municipal Program called PICA. NYC Municipal employees can contact Accredo Customer Service at (800) 467-2006 and inquire about drug coverage.

The symbol [PA] next to a drug name indicates that this medication is subject to the Prior Authorization Program.

The symbol [ST] next to a drug name indicates that this medication is subject to the Step Therapy Program.

The symbol [QD] next to a drug name indicates that this medication is subject to the Quantity Duration Program.

The symbol [CPA] next to a drug name indicates that this medication is subject to the Client Prior Authorization Program.

The symbol [SF] next to a drug name indicates that this medication is subject to the Split-Fill Program.

All rights in the product names of all third-party products listed, whether or not appearing with the trademark symbol, belong exclusively to their respective owners. Subject to change.

- ◆ *Yervoy*<sup>™</sup> (ipilimumab) [PA] [QD]
- ◆ *Zaltrap*<sup>®</sup> (afibercept) [PA]
- ◆ *Zarxio* (GENERIC) [PA] [PICA]
- Zavesca*<sup>®</sup> (miglustat) [QD][CPA]
- ◆ *Zelboraf*<sup>™</sup> (vemurafenib) [PA] [QD] [PICA] [SF]
- Zemaira*<sup>®</sup> (alpha [1]-proteinase inhibitor [human])  
[PA]
- Zepatier*<sup>™</sup> (elbasvir/grazoprevir) [PA] [QD] [SF]
- Zinbryta*<sup>™</sup> (daclizumab) [PA] [PICA]
- ◆ *Zoladex*<sup>®</sup> (goserelin acetate) [PA] [PICA]
- ◆ *Zolinza*<sup>®</sup> (vorinostat) [PA] [QD] [PICA] [SF]
- Zomactor*<sup>®</sup> (somatropin [rDNA origin]) [PA] [PICA]
- Zorbtive*<sup>®</sup> (somatropin [rDNA origin]) [PA] [PICA]
- ◆ *Zykadia*<sup>™</sup> (ceritinib) [PA] [PICA] [QD] [SF]
- ◆ *Zytiga*<sup>™</sup> (abiraterone acetate) [PA] [QD] [PICA]  
[SF]

◆ If the indication is CANCER, and the drug is subject to management by EviCore Comprehensive Oncology Management Program, please contact (888) 910-1199 for additional assistance. Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization.

\*This specialty drug may be filled two (2) times at a retail pharmacy on an emergency basis. Subsequent fills must be made through Accredo's mail order delivery.

[PICA] = Specialty drug is available through the NYC Municipal Program called PICA. NYC Municipal employees can contact Accredo Customer Service at (800) 467-2006 and inquire about drug coverage.

The symbol [PA] next to a drug name indicates that this medication is subject to the Prior Authorization Program.

The symbol [ST] next to a drug name indicates that this medication is subject to the Step Therapy Program.

The symbol [QD] next to a drug name indicates that this medication is subject to the Quantity Duration Program.

The symbol [CPA] next to a drug name indicates that this medication is subject to the Client Prior Authorization Program.

The symbol [SF] next to a drug name indicates that this medication is subject to the Split-Fill Program.

All rights in the product names of all third-party products listed, whether or not appearing with the trademark symbol, belong exclusively to their respective owners. Subject to change.